BCL2L1 and Miyoshi myopathy: Additionally, our preliminary analysis of bone marrow samples from relapse/refractory MM patients showed that of the 22 samples analyzed, only 2 were sensitive to DT2216 (cell death ≥ 50% at 150nM), suggesting that a small group of relapse/refractory MM patients are dependent on BCLXL and could potentially receive therapeutic benefit from DT2216.